XERS - NASDAQ
Xeris Biopharma Holdings, Inc.
$5.89
-1.8%Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
At a Glance
Live SnapshotXeris Biopharma Holdings, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Minimal profitability after all expenses. Limited financial flexibility for reinvestment or shareholder returns.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Xeris Biopharma Holdings, Inc. Income Statement
XERS • NASDAQ
| Xeris Biopharma Holdings, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||
291.8M | 203.1M | 163.9M | 110.2M | 49.6M | 20.4M | 2.7M | 2.5M | 1.6M | 1.1M | |
GROSS PROFIT | ||||||||||
(53.4M) | (36.8M) | (28.6M) | (22.6M) | (13.3M) | (9.3M) | (1.6M) | (42K) | (4K) | (8K) | |
238.4M | 166.2M | 135.3M | 87.6M | 36.3M | 11.1M | 1.1M | 2.4M | 1.6M | 1.1M | |
OPERATING INCOME | ||||||||||
(213.5M) | (199.9M) | (179.3M) | (169.6M) | (151.4M) | (94.7M) | (123.5M) | (61.8M) | (28.2M) | (14.3M) | |
(182.4M) | (163.5M) | (146.1M) | (137.7M) | (125.7M) | (73.7M) | (63.1M) | (21.1M) | (8M) | (4.1M) | |
(31.2M) | (25.6M) | (22.3M) | (21M) | (25.2M) | (20.9M) | (60.4M) | (40.7M) | (20.2M) | (10.2M) | |
24.9M | -33.6M | -44M | -81.9M | -115.2M | -83.5M | -122.4M | -59.3M | -26.6M | -13.2M | |
PRE-TAX INCOME | ||||||||||
(29.1M) | (33.2M) | (26.6M) | (14.1M) | (7.2M) | (7.4M) | (7.2M) | (2.5M) | (2K) | (2K) | |
-24.3M | -27.9M | -21.9M | -11.5M | -6.9M | -2.9M | -4.4M | -932K | 122K | 3K | |
(0.0) | (10.8M) | (10.8M) | (10.8M) | (550K) | (0.0) | (0.0) | (0.0) | -1K | -5K | |
-24.3M | -23.5M | -19.5M | -14.1M | -7.6M | -7.7M | -3.7M | -736K | 75K | 22K | |
554K | -57.1M | -63.5M | -96.1M | -122.7M | -91.3M | -126M | -60.1M | -26.6M | -13.2M | |
NET INCOME | ||||||||||
(0.0) | -2.3M | -1.2M | -1.4M | (0.0) | -110K | -458K | (0.0) | (1K) | -3K | |
554K | -54.8M | -62.3M | -94.7M | -122.7M | -91.1M | -125.6M | -60.1M | -26.6M | -13.2M |
SEC Filings
XERS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 21, 2026 | April 20, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 27, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 01, 2025 | December 01, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 |
Related Guides
Continue your XERS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.